Genetics in Medicine : Official Journal of the American College of Medical Genetics
-
Publication Venue For
-
Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance..
23:306-315.
2021
-
Health and economic outcomes of newborn screening for infantile-onset Pompe disease.
2020
-
Response to Heiner-Fokkema et al..
22:1917-1918.
2020
-
An autosomal dominant neurological disorder caused by de novo variants in FAR1 resulting in uncontrolled synthesis of ether lipids
2020
-
Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models..
21:71-80.
2019
-
A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone..
20:132-141.
2018
-
Cognitive outcomes and age of detection of severe mucopolysaccharidosis type 1..
19:975-982.
2017
-
Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation..
19:121-126.
2017
-
Genetic causal attributions for weight status and weight loss during a behavioral weight gain prevention intervention..
18:476-482.
2016
-
CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy.
17:912-918.
2015
-
Summarizing polygenic risks for complex diseases in a clinical whole-genome report..
17:536-544.
2015
-
Informed consent for biobanking: consensus-based guidelines for adequate comprehension..
17:226-233.
2015
-
Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys..
17:58-62.
2015
-
Jaffe-Campanacci syndrome, revisited: detailed clinical and molecular analyses determine whether patients have neurofibromatosis type 1, coincidental manifestations, or a distinct disorder..
16:448-459.
2014
-
Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary's Advisory Committee on Heritable Disorders in Newborns and Children..
16:183-187.
2014
-
Response to Rosenberg et al..
15:754.
2013
-
Managing incidental genomic findings: legal obligations of clinicians..
15:624-629.
2013
-
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer..
15:203-211.
2013
-
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease..
15:123-131.
2013
-
Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal)..
14:779-786.
2012
-
Tilting at windmills no longer: a data-driven discussion of DTC DNA ancestry tests..
14:586-593.
2012
-
Molecular genetic testing for fragile X syndrome: laboratory performance on the College of American Pathologists proficiency surveys (2001-2009)..
14:306-312.
2012
-
Enhancing geneticists' perspectives of the public through community engagement..
14:243-249.
2012
-
Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions..
13:723-728.
2011
-
"That's a good question": university researchers' views on ownership and retention of human genetic specimens..
13:569-575.
2011
-
Glycogen storage disease type III diagnosis and management guidelines (vol 12, pg 446, 2010).
12:566-566.
2010
-
Impact of gene patents and licensing practices on access to genetic testing for cystic fibrosis..
12:S194-S211.
2010
-
Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers..
12:S15-S38.
2010
-
Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome..
12:S111-S154.
2010
-
Incorporating ethnicity into genetic risk assessment for Alzheimer disease: the REVEAL study experience..
10:207-214.
2008
-
The feasibility of online genetic testing for lung cancer susceptibility: Uptake of a web-based protocol and decision outcomes (Genetics in Medicine (2008) 10, (127-130)).
10:228.
2008
-
The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes..
10:121-130.
2008
-
Update on psychiatric genetics..
9:332-340.
2007
-
Erratum: Pompe disease diagnosis and management guidelines (Genetics in Medicine (May 2006) 8 (267-288)).
8:382.
2006
-
Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease..
8:313-317.
2006
-
Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease..
8:302-306.
2006
-
Diagnostic challenges for Pompe disease: an under-recognized cause of floppy baby syndrome..
8:289-296.
2006
-
Electrocardiographic response to enzyme replacement therapy for Pompe disease..
8:297-301.
2006
-
Physical therapy management of Pompe disease..
8:318-327.
2006
-
Pompe disease diagnosis and management guideline..
8:267-288.
2006
-
The use of acarbose inhibition in the measurement of acid alpha-glucosidase activity in blood lymphocytes for the diagnosis of Pompe disease..
8:307-312.
2006
-
Recurrence risks for neural tube defects in siblings of patients with lipomyelomeningocele..
7:64-67.
2005
-
Mutations in genes required for T-cell development: IL7R, CD45, IL2RG, JAK3, RAG1, RAG2, ARTEMIS, and ADA and severe combined immunodeficiency: HuGE review..
6:16-26.
2004
-
The genetics workforce and workload..
5:55-57.
2003
-
Contribution of sickle cell disease to the occurrence of developmental disabilities: a population-based study..
3:181-186.
2001
-
Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial..
3:132-138.
2001
-
Exon 10b of the NF1 gene represents a mutational hotspot and harbors a recurrent missense mutation Y489C associated with aberrant splicing..
1:248-253.
1999